Amer Sports Inc vs Cassava Sciences Inc — how do they compare? Amer Sports Inc trades at $34.76 (market cap $20.25B), while Cassava Sciences Inc trades at $1.17 (market cap $57.49M). The key difference: Amer Sports Inc is far larger — about 352.2× Cassava Sciences Inc's market cap, and Amer Sports Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| AS | FLNA | |
|---|---|---|
Market Cap | $20.25B | $57.49M |
Sector | Technology | Health |
52-Week High | $41.96 | $4.64 |
52-Week Low | $29.54 | $1.16 |
Enterprise Value | $20.56B | -$29.09M |
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $34.80, up 2.75% today, with strong Q1 2026 earnings beating estimates and raised full-year guidance. Technicals show a bearish trend near key support at $33, while fundamentals reflect robust revenue growth of 32% year-over-year and a 58.23% gross margin. Analyst sentiment is overwhelmingly positive with 12 buy ratings and a $56 consensus target, indicating 61% upside potential from current levels.
The outlook remains favorable given earnings momentum and raised guidance, but risks include reliance on Arc'teryx brand sustainability and competitive pressures. Valuation metrics like a P/E of 43.49 suggest premium pricing, requiring continued execution to justify upside. Net positive cash flow and institutional support provide stability amid technical weakness.
FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.
While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.
Trailing returns across standard periods
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →